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proliferation
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MATERIALS AND METHODS
Immunohistochemistry
ANXA2 immunohistochemistry was conducted on 5 
μm sections from 89 FFPE GBM specimens with standard 
procedures. Briefly, sections were re-hydrated and then 
antigen retrieval was performed by incubation with 
citrate buffer 0.01 M pH6 at 95°C. After saturation with 
the appropriate normal serum, slides were incubated 
with an anti-ANXA2 antibody (clone 5/Annexin II; BD 
Bioscience, San Jose, CA; Supplementary  Table S7). 
After incubation, sections were washed and incubated with 
species-specific biotin-conjugated secondary antibodies 
(Vector Laboratories Inc. Burlingame, CA; Supplementary 
Table S7). ANXA2 expression was revealed by using 
the Dako Liquid DAB+ Substrate Chromogen System 
(Dako, Glostrup, Denmark) according to manufacturer’s 
guidelines. Tissues were counterstained with Meyer’s 
Hematoxylin and images acquired with a Zeiss Imager 
M1 microscope (Carl Zeiss, Oberkochen, Germany). The 
specificity of each staining procedure was confirmed by 
replacing the primary antibodies with an Isotype control. 
The expression level of ANXA2 was scored using 
a combined method accounting for both the staining 
intensity and the percentage of positive stained cells. 
The resulting combined score was calculated as the 
multiplication of the score accounting for the percentage 
of ANXA2+ cells (0–6) and the intensity score (0–3). 
ANXA2 stained slides were independently evaluated by 
two different pathologists.
Transfection of primary GBM cells
To achieve a suitable gene silencing, GBM 
cells were transfected with 200pmol of two different 
small interfering RNAs (siRNAs) against ANXA2 as 
well as with a non targeting siRNA (siNEG) using the 
Lipofectamine RNAiMAX reagent (Thermo Fisher 
Scientific, Waltham, MA) according to manufacturer’s 
instructions. siANXA2#1 siRNA sequence: (RNA)-
5′-GCG ACU ACC AGA AAG CGC UGC UGU 
A-3′; siANXA2#2 siRNA sequence: (RNA)-5′-GAC 
UGA UCU GGA GAA GGA CAU UAU U-3′ (Stealth 
RNAi™; siANXA2#1 cat.# 10620318, siANXA2#2 cat.# 
10620319). 
For ANXA2-overexpression experiments, the 
ANXA2 complete cDNA sequence was cloned into a 
pcDNA3.1 empty vector in order to generate an expression 
vector named pcDNA3.1-ANXA2. Primers used for 
ANXA2 coding sequence amplification are listed in 
Supplementary  Table S8. In over-expression experiments, 
GBM cells were transfected with an opportune quantity 
of pcDNA3.1-ANXA2 or pcDNA3.1 empty vector using 
the TransIT®-LT1 Transfection Reagent (Mirus Bio LLC, 
Madison, WI) according to manufacturer’s instructions. 
Transfected cells were then cultured for 24–96 h 
depending on the experimental endpoints. The analysis of 
silencing or overexpression specificity was achieved by 
WB and qRT-PCR.
Western blot
Equal amounts of proteins (10 µg) extracted 
from primary GBM cells were resolved using a SDS-
PAGE gels and transferred to polyvinylidene difluoride 
(PVDF) Immobilon-p membrane (Merk-Millipore, 
Darmstadt, Germany). Membranes were blocked with 
I-block™ (Thermo Fisher Scientific, Waltham, MA) 
for at least 1 hour at room temperature and then were 
incubated overnight at 4°C under constant shaking with 
the primary antibody against ANXA2 (clone 5/Annexin 
II; BD Bioscience, San Jose, CA; Supplementary 
Table S7). Membranes were next incubated with HRP-
labeled goat anti-mouse IgG (1:50000; Sigma-Aldrich, 
Milan, Italy; Supplementary  Table S7) for 60 minutes. 
All membranes were visualized using ECL Select (GE 
Healthcare, Catania, Italy) and exposed to Amersham 
Hyperfilm ECL (GE Healthcare). β-actin staining (Sigma-
Aldrich S.r.l., Milan, Italy; Supplementary  Table S7) was 
used as loading control. Original unmodified membrane 
acquisitions are reported as Supplementary  Fig. S12.
Reverse transcription and real-time PCR
RNA was extracted from GBM cells using TRIzol 
reagent (Thermo Fisher Scientific, Waltham, MA) 
according to manufacturer’s instructions and 1–2 µg of 
total RNA reverse-transcribed using SuperScript RNAse 
II Reverse Transcriptase (Thermo Fisher Scientific, 
Waltham, MA). Quantitative RT-PCR reactions were 
run in triplicate using Platinum SYBR Green Q-PCR 
Super Mix (Thermo Fisher Scientific, Waltham, MA). 
Fluorescent emission was recorded in real-time (Sequence 
Detection System 7900HT, Applied Biosystems, Foster 
City, CA). The specificity of primers was confirmed for 
every PCR run by dissociation curve analysis. Primers 
used are listed in Supplementary  Table S8 and their 
specificity was confirmed by the software Human BLAT 
Search (http://genome.ucsc.edu). Relative RNA quantities 
were normalized to GUSB according to the ΔΔCt Method.
Immunofluorescence
GBM cells were cultured on 4-well chamber slides 
(BD Bioscience, San Jose, CA), treated depending on 
the experimental plan. After treatment, cells were fixed 
in cold 4% formaldehyde and stored at +4°C prior to 
analysis. Primary antibody staining was performed for 
Nestin (Merk-Millipore, Darmstadt, Germany), Ki67, 
GFAP, S100 (all from Dako, Glostrup, Denmark), MAP2 
(Sigma-Aldrich, Milan, Italy), OSP (Abcam, Cambridge, 
UK), ANXA2 (clone C-10; Santa Cruz Biotechnology, 
Santa Cruz, CA), FITC-coniugated Phalloidin (1:1000; 
Sigma-Aldrich, Milan, Italy) and Sox2 (Cell Signaling 
Technology). For additional details on antibodies used for 
immunofluorescence, please see Supplementary  Table S7. 
After incubation, cells were washed and incubated with 
species-specific secondary antibodies conjugated to 
Alexa dyes (Thermo Fisher Scientific, Waltham, MA; 
Supplementary  Table S7). Cells were counterstained 
with DAPI (1:10000; Sigma-Aldrich, Milan, Italy) to 
measure total cell number. Staining was visualized by 
epifluorescence with a ViCo microscope (Vico, Nikon, 
Melville, NY).
Cytofluorimetric analyses
CD133 were incubated with anti-human CD133 
(clone CD133/1-PE; Miltenyi Biotec, Bergisch Gladbach, 
Germany) as previously described (Supplementary 
Table S7). Relative percentages of different subpopulations 
were calculated based on live gated cells (as indicated by 
physical parameters, side scatter and forward scatter). 
Unlabeled cells and cells incubated with appropriate 
isotype control antibodies were first acquired to ensure 
labelling specificity. To perform cell cycle analysis, 
GBM cells were collected after 72 h of treatment (anti-
ANXA2 antibody, ANXA2 silencing or over-expression), 
centrifuged and fixed with ice-cold ethanol (70%). Cells 
were then treated with permeabilization buffer containing 
RNAse A, 0.1% Triton X-100 and propidium iodide (PI) 
at room temperature for 30 minutes prior to analysis. 
DNA histograms were analyzed using Multi- Cycle® for 
Windows (Phoenix Flow Systems, San Diego, CA). 
Analysis of BrdU incorporation was performed 
with a BrdU Staining Kit for Flow Cytometry 
FITC (eBioscience, Hatfield, UK) according to the 
manufacturer’s instructions. BrdU was incubated with 
cells for 72 h. For all stainings, samples were acquired 
on a Cytomic FC500 flow cytometer (Beckman Coulter, 
Brea, CA).
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Supplementary Figure S1: ANXA2 protein expression is upregulated in GBM. Box plot showing the comparison between 
ANXA2 IHC scores of low grade gliomas/secondary GBMs (N = 20) and primary GBM tumours (N = 69). Significance has been calculated 
by Mann-Whitney test.
Supplementary Figure S2: ANXA2 protein expression impacts glioma patient survival. (A–D) Kaplan Meier curves showing 
PFS and OS of glioma patients divided in four subgroups (A and C) depending on ANXA2 IHC score (ANXA2 Very Low: IHC score < 
25° percentile; ANXA2 Low: IHC score < 50° percentile; ANXA2 High: IHC score < 75° percentile; ANXA2 Very High: IHC score ≥ 
75° percentile). Right panels reports PFS (B) and OS (D) of glioma patients divided in two subgroups depending on ANXA2 IHC score 
(ANXA2 Very Low: IHC score < 25° percentile; ANXA2 High: IHC score > 25° percentile). (E and F) Kaplan Meier curves showing PFS 
(E) and OS (F) of GBM patients divided in four quartiles on the basis of ANXA2 IHC score as previously reported.
Supplementary Figure S3: ANXA2 mRNA expression impacts GBM patient survival. (A and B) Kaplan Meier curves 
showing OS of GBM patients retrieved from TCGA (A; N = 519 patients) [1, 2] or GSE13041 (B; N = 191 patients) [3] datasets. GBM 
patients have been divided in four quartiles on the basis of ANXA2 mRNA expression levels as previously described. (C and D) Kaplan 
Meier curves showing PFS of GBM patients from TCGA divided in four quartiles (C) or in two subgroups (D; < or ≥ 25° percentile) on the 
basis of ANXA2 mRNA expression levels.
Supplementary Figure S4: ANXA2 prognostic potential is not dependent on the GBM molecular subclass. (A and B) 
Kaplan Meier curves showing OS (A) and PFS (B) of GBM patients retrieved from TCGA (N = 172) and classified according to the 
molecular subtypes by Verhaak et al. [4]. (C–J) Kaplan Meier curves reporting survival analysis (OS, left and PFS, right panels) of TCGA 
patients divided in two subgroups on the basis of ANXA2 expression (< or ≥ 25° percentile) in the Proneural (C and D), Neural (E and F), 
Classical (G and H) and Mesenchymal (I and J) molecular subtypes.
Supplementary Figure S5: GSEA analysis of differentially expressed genes in ANXA2 High vs. ANXA2 Very Low GBM 
patients. (A) Venn diagrams reporting the number of differentially expressed genes between GBM tumours expressing high levels (ANXA2 
High; ≥ 25° percentile) or very low (ANXA2 Very Low; < 25° percentile) levels of ANXA2 mRNA in patients retrieved from TCGA (orange) 
or GSE13041 (green) datasets. (B) GSEA of commonly up-regulated genes in ANXA High patients from TCGA and GSE13041 datasets 
showing positive enrichment for genes of the Mesenchymal molecular subtype [4], EMT and cell migration, and negative enrichment for 
genes of the Proneural molecular subtype [4]. Plots were generated by c2 curated gene sets in the GSEA MSigDatabase. The green curves 
show the enrichment score and reflects the degree to which each gene (black vertical lines) is represented at the top or bottom of the ranked 
gene list. The heat map indicates the relative abundance (red to blue) of the genes specifically enriched in the ANXA2 High as compared 
with the ANXA2 Very Low GBM patients.
Supplementary Figure S6: ANXA2 protein expression in primary GBM cell cultures. Western Blot analysis of ANXA2 
protein expression in seven primary GBM cells used in this study. β-Actin expression has been used as loading control. 10 μg of protein 
lysate has been loaded in each lane.
Supplementary Figure S7: Scratch assay on GBM and SVZ-derived cells at different time points. Representative images 
showing the ability of GBM cells to close the wound at 24, 48 and 72 h after scratching the cell monolayer during scratch assays performed 
on primary GBM cells treated with the monoclonal anti-ANXA2 antibody (A; HuTuP175) or ANXA2 over-expressing (B; HuTuP83) 
cells and SVZ-derived SC23 normal cells treated with the monoclonal anti-ANXA2 antibody (C) with relative quantification (N = 8). 
The distance between the two edges of the scratch is marked in brown and has been quantified by using Adobe Photoshop CS6. Original 
magnification 10×; bar:50 μm. ****p < 0.001 by one-way ANOVA analysis.
Supplementary Figure S8: Modulation of primary GBM cell invasion by ANXA2 inhibition, gene silencing or over-
expression. (A) Representative images of primary GBM cells (HuTuP176), endowed with reticulate growth, plated on Matrigel-coated 
dishes and treated with anti-ANXA2 antibody for the indicated timepoints. Original magnification 4x. (B, C and D) Bar graphs reporting 
the absolute cell number of BME-invaded GBM cells upon ANXA2 inhibition (B; N = 3 for HuTuP13 and HuTuP175), gene silencing 
(C; N = 3 for HuTuP13 and HuTuP174) or over-expression (D; N = 4 for HuTuP83) as quantified by Cultrecoats® BME-based assays as 
described in the Methods section. 
Supplementary Figure S9: Immunofluorescence analysis of ANXA2 inhibited/silenced GBM cells. (A–C) Representative 
immunofluorescence images of GBM cells treated either with isotype or ANXA2 antibody and double stained for GFAP (red)/phalloidin 
(green) (A), MAP2 (red)/GFAP (green) (B) and Nestin (red)/OSP (green) (C). Images show a peculiar distribution of GFAP and Actin 
fibers within the cell cytoplasm. (D and E) Representative immunofluorescence images showing primary GBM cells (HuTuP13) silenced 
for ANXA2 and stained with anti-ANXA2 antibody (green; D) and bar ghaph reporting relative quantification of ANXA2+ cells (E). Cell 
nuclei have been counterstained with DAPI (blue). Original magnification 10–20x. ***p < 0.001 by one-way ANOVA analysis.
Supplementary Figure S10: Long term anti-proliferative effects of ANXA2 inhibition/silencing in GBM cells. Growth 
curves generated by cell count (trypan blue exclusion) at different time-points after ANXA2 inhibition (HuTuP175; A) or gene silencing 
(HuTuP13; B). *p < 0.05, **p < 0.001 by one-way ANOVA analysis.
Supplementary Figure S11: Impact of aggressive treatment on GBM patients depending on ANXA2 expression. Kaplan 
Meier curves reporting OS of GBM patients either treated with a single cycle of mono or concurrent therapy (Less Intensive), or by 
additional cycles of treatment (More Intensive) depending on their transcriptional expression of ANXA2 (< or ≥ 25° percentile in (A) and 
(B) respectively).
Supplementary Figure S12: Unedited acquisitions of Western Blot membranes. (A) Unedited acquisitions of WB showed in 
Figure 2D. (B) Unedited acquisitions of WB showed in Figure 2E. (C) Unedited acquisitions of WB showed in Supplementary Figure S6.
Supplementary Table S1: Newman-Keuls multiple comparisons test from GSE4290
Comparison p value
Normal Brain vs. Glioma II p < 0.05
Normal Brain vs. Glioma III p < 0.001
Normal Brain vs. GBM p < 0.0001
Glioma II vs. Glioma III p < 0.05
Glioma II vs. GBM p < 0.0001
Glioma III vs. GBM p < 0.001
Supplementary Table S2: Clinical characteristics of glioma patients included in survival and multivariate 
analyses. See Supplementary_Tables_S2
Supplementary Table S3: Common differentially expressed genes between TGCA and GSE13041 derived 
from comparison between ANXA2 Very Low and ANXA2 High patients. See Supplementary_Tables_S3
Supplementary Table S4: primary GBM cells used in the study
Code Diagnosis Age (y) Sex
HuTuP13 GBM 67 male
HuTuP53 GBM 70 male
HuTuP82 GBM 50 male
HuTuP83 GBM 55 male
HuTuP107 GBM 65 male
HuTuP174 GBM 69 male
HuTuP175 GBM 54 female
HuTuP176 GBM 59 male
Supplementary Table S5: Differentially expressed genes between Isotype and anti-ANXA2 antibody 
treated GBM cells. See Supplementary_Tables_S5
Supplementary Table S6: Summary of Log-rank analysis for ANXA2-dependent Risk Score on TCGA, 
GSE13041, GSE17536, E-MTAB-365 and GSE31210  cohorts of cancer patients
Tumour type
(origin of data) Survival ANXA2 status
Median
Survival
(months)
Log-rank (Mantel-
Cox)
p value
Hazard Ratio 
(logrank)
Risk score low/
Risk score high
GBM from TCGA
PFS
Risk Score High
Risk Score Low
7.83
8.72
0.019 1.288
OS
Risk Score High
Risk Score Low
12.93
14.41
0.0261 1.242
GBM from 
GSE13041 OS
Risk Score High
Risk Score Low
11.7
13.55
0.0486 1.353
Colon cancer from 
GSE17536 DSS
Risk Score High
Risk Score Low
77.6
N.D.
0.006 2.149
Breast cancer from 
E-MTAB-365 RFS
Risk Score High
Risk Score Low
N.D.
N.D.
0.002 1.739
Lung 
adenocarcinoma 
from GSE31210
RFS
Risk Score High
Risk Score Low
N.D.
N.D.
0.0605 1.61
N.D. Not Determined.
Supplementary Table S7: antibodies used in this study
Antibody (Clone) Host Use Dilution Producer Catalog#
Annexin II (5/Annexin II) mouse IHC 1:2000 BD Bioscience 610068
Annexin II (C-10) mouse
IF
In vitro neutralization
In vivo neutralization
1:100
5-20μg/ml
2μg/egg
Santa Cruz 
Biotechnology
sc-28385
β-actin (AC-74) mouse WB 1:20000 Sigma-Aldrich A5316
CD133-PE (AC133/1) mouse FC 1:25 Miltenyi Biotec 130-080-801
GFAP rabbit IF 1:1000 Dako Z0334
Ki67 (MIB-1) mouse IF 1:100 Dako M7240
MAP2 (AP-20) mouse IF 1:100 Sigma-Aldrich M1406
Nestin (10C2) mouse IF 1:200 Millipore MAB5326
OSP rabbit IF 1:200 Abcam ab53041
S100 rabbit IF 1:400 Dako Z0311
Sox2 (D6D9) rabbit IF 1:200
Cell Signaling 
Technology
3579
anti-mouse-Alexa594 goat IF 1:1000 Life Technologies A11005
anti-mouse-Alexa488 goat IF 1:1000 Life Technologies A11001
anti-rabbit-Alexa488 goat IF 1:1000 Life Technologies A11008
Anti-rabbit-Alexa594 goat IF 1:1000 Life Technologies A11012
anti-mouse-HRP goat WB 1:50000 Perkin Elmer NEF822001EA
IHC: Immunohistochemistry; IF: immunofluorescence; WB: western blot; FC: flow cytometry.
Supplementary Table S8: Sequence of primers used in this study
Gene  Sequence (5′-3′)
ANXA2 forward GGGGACGCGAGATAAGGTCC
ANXA2 reverse CGCTTTCTGGTAGTCGCCCT
ANXA2_CDS forward ATGGGCCGCCAGCTAGCG
ANXA2_CDS reverse TCAGTCATCTCCACCACACAGGTAC
ANXA2_BamHI-5′ ACTGGGATCCATGGGCCGCCAGCTAGCG
ANXA2_XhoI-3′ ACTGCTCGAGTCAGTCATCTCCACCACACAGGTAC
ADAM12 forward CATCGGCATGGCCCCAATCA
ADAM12 reverse GGCTGCACCAAGGGGATTGT
COL5A1 forward CCCTGACAAGAAGTCCGAAGGG
COL5A1 reverse GCAGCCGCAGGAAGGTCAT
DNAH9 forward GGCCCGACCGGATGACCTAT
DNAH9 reverse TCCACCCCTGGAGACAGGATG
FBN1 forward GCTGCGAGTGTCCCTTTGGT
FBN1 reverse GGGCTCAAATCCCTCCTCGC
HMMR forward GGAGTGCCAGTCACCTTCAGT
HMMR reverse ACATCATAAGCACCTGGAGATGG
PLAT forward GCCCGATTCAGAAGAGGAGCC
PLAT reverse ACTGTGCCCTGCCACTGTTG
SDK2 forward CCGTCAACGACGTGGGGAAA
SDK2 reverse ACTGGTTGGTTCGACCGCTG
SEMA5A forward CCCAGGCGCTGGATGACTG
SEMA5A reverse GTGTGGAAAGTGCCAAGGAGAGAG
COCH forward AAGGGAGAGCCCCAACAAGAAC
COCH reverse AGGTCATCCAGAGGTGCCCAA
MYO1B forward GGGTGGAAATGCCGCACACA
MYO1B reverse CGAGCCTTCCAACCCCGGATA
MYL5 forward GTACCGACGCCGAGGAGACC
MYL5 reverse CGATGGAGGCGAACTGGAACA
CCNA2 forward CGTGAAGATGCCCTGGCTTTTA
CCNA2 reverse TGGTACTTCATTAACACTCACTGGC
MKI67 forward GCCTGCTCGACCCTACAGAG
MKI67 reverse ACTGCGGTTGCTCCTTCACTG
CDCA3 forward GGACTCAGATCCCCGCTCTC
CDCA3 reverse GGTACCCAGAGGCAAGTCCAA
CDK1 forward AAGCCGGGATCTACCATACCC
CDK1 reverse GCAGTACTAGGAACCCCTTCCTCT
KIF14 forward CCTCTGCAGGAAAAGACCCCT
KIF14 reverse CGTGTCAGGGTGTTCCACAGTT
KIF20A forward GAACGAACGCAGCGCGTAAT
KIF20A reverse GCCTAGGTCCGAAGACGTGC
GUSB forward GAAAATACGTGGTTGGAGAGCTCATT
GUSB reverse CCGAGTGAAGATCCCCTTTTTA
